ASCO2021 releases new recommendations on systemic therapeutic doses for obese adult cancer patients

The American Society of Clinical Oncology ( ASCO ) approved new recommendations for appropriate doses of systemic anticancer drugs in obese adult cancer patients
.
The update of this guideline is based on the evidence collected from a systematic review of the literature on cancer chemotherapy, immunotherapy, and targeted therapy in obese adults published from November 1, 2010 to March 27, 2020

.

ASCO Immunization

Evaluate dosage recommendations for new drugs

Evaluate dosage recommendations for new drugs

There has always been concern about the potential toxicity of chemotherapy drugs to overweight or obese patients
.
The dose of cancer treatment is usually based on the patient's body surface area (a combination of the patient's height and weight), so the heavier the patient, the greater the amount of medication they receive

.

Based on available evidence, the ASCO expert panel recommended in 2012 that overweight and obese patients receive the actual calculated dose, regardless of their weight
.
However, since then, many new drugs have been approved for cancer patients, including tyrosine kinase inhibitors, targeted monoclonal antibodies, and more recently immunotherapy

.

Enhancing full body weight dosage recommendations

Enhancing full body weight dosage recommendations

This latest update addresses 6 clinical problems of adult obese cancer patients, in particular: 1.
The safety and effectiveness of adequate, weight-based cytotoxic chemotherapy; 2.
The use of fixed doses of cytotoxic chemotherapy; 3.
The safety and effectiveness of approved doses of checkpoint inhibitors (fixed-dose or weight-based); 4.
The safety and effectiveness of approved doses of targeted therapy (fixed-dose or weight-based); 5.
In the case of toxicity, modify the systemic anti-tumor treatment dose or plan; 6.
The best way to calculate the body surface area
.

Based on the review of the evidence from 60 studies that meet the eligibility criteria, the expert panel recommends the following:

The expert group recommends as follows: The expert group recommends as follows:

1.
chemotherapy heavy dose of all, regardless of Obesity; 2 US Food and Drug.
Management Authority ( the FDA ) approved only for specific cytotoxic drug use fixed-dose chemotherapy; for example, bleomycin; 3 in all patients Use FDA-approved prescription information for immune checkpoint inhibitors, regardless of obesity; 4.
Use FDA-approved prescription information for targeted therapy for all patients, regardless of obesity; 5.
According to established dose reduction guidelines for all patients, Reduce the dose of systemic anti-tumor therapy, regardless of whether the patient is obese or not; 6.
Use any standard formula to calculate body surface area
.

1.
chemotherapy heavy dose of all, regardless of Obesity; 2 US Food and Drug.
Management Authority ( the FDA ) approved only for specific cytotoxic drug use fixed-dose chemotherapy; for example, bleomycin; 3 in all patients Use FDA-approved prescription information for immune checkpoint inhibitors, regardless of obesity; 4.
Use FDA-approved prescription information for targeted therapy for all patients, regardless of obesity; 5.
According to established dose reduction guidelines for all patients, Reduce the dose of systemic anti-tumor therapy, regardless of whether the patient is obese or not; 6.
Use any standard formula to calculate body surface area
.
1.

chemotherapy heavy dose of all, regardless of Obesity; 2 US Food and Drug.

When actual body weight is used to determine the dose, there is no evidence of overdose toxicity.

One step closer to achieving fairness in cancer treatment

These latest recommendations will lead to improvements in care, especially in people who are already at greater risk of suboptimal outcomes

.

The biggest improvement will be those patients who are cared for in practice, who continue to follow the original guidelines and are now updating the guidelines, which should provide oncologists with the support they need
.
Minority group members and other marginalized cancer patients are more likely to have a higher body size, and the entire body weight dose is closer to achieving fairness in their care

.

Both the original 2012 guidelines and the 2021 update of the guidelines have strengthened and established important recommended care for systemic therapeutic doses for overweight or obese adult cancer patients
.
The ASCO expert group recommends that this patient group should receive standardized and recommended treatments to reduce undesirable and potentially harmful dose differences that may occur in different practice environments

.

Both the original 2012 guidelines and the 2021 guidelines update strengthened and established important recommendations for the care of systemic therapeutic doses for overweight or obese adult cancer patients.
The initial 2012 guidelines and the 2021 guidelines update both strengthened and established the care for overweight or obese adult cancer patients.
Important recommendations for systemic therapeutic doses for obese adult cancer patients.
The ASCO expert panel recommends that this patient population should receive standardized and guideline-recommended treatments to reduce undesirable and potentially harmful dose differences that may occur in different practice environments
.
The ASCO expert group recommends that this patient group should receive standardized and recommended treatments to reduce undesirable and potentially harmful dose differences that may occur in different practice environments
.
Leave a message here